Kathy Dujardin

Summary

Affiliation: CHRU de Lille
Country: France

Publications

  1. doi Apathy may herald cognitive decline and dementia in Parkinson's disease
    Kathy Dujardin
    Universite Lille Nord de France, France
    Mov Disord 24:2391-7. 2009
  2. ncbi Is the paced auditory serial addition test (PASAT) a valid means of assessing executive function in Parkinson's disease?
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, Lille, France
    Cortex 43:601-6. 2007
  3. ncbi [Apathy an neurodegenerative diseases: pathophysiology, diagnostic evaluation, and treatment]
    K Dujardin
    Faculte de Medecine, Université du Droit et de la Santé de Lille, Institut Fédératif de Recherche IFR 114, Neurosciences, Cedex
    Rev Neurol (Paris) 163:513-21. 2007
  4. ncbi Characteristics of apathy in Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and Lille University Hospital, Lille, France
    Mov Disord 22:778-84. 2007
  5. doi Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and University Medical Center, Lille, France
    J Neurol 257:79-84. 2010
  6. doi The Lille Apathy Rating Scale: validation of a caregiver-based version
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and Lille University Hospital, Lille, France
    Mov Disord 23:845-9. 2008
  7. ncbi Deficits in decoding emotional facial expressions in Parkinson's disease
    Kathy Dujardin
    Neurology A Department, Neurology and Movement Disorders Unit, Salengro Hospital, EA 2683, Lille University Hospital, F 59037 Lille Cedex, France
    Neuropsychologia 42:239-50. 2004
  8. doi Methylphenidate : a treatment for Parkinson's disease?
    David Devos
    Department of Medical Pharmacology, EA 1046, Lille Nord de France University, CHU Lille, Lille, France
    CNS Drugs 27:1-14. 2013
  9. ncbi Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial
    David Devos
    Department of Medical Pharmacology, Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 85:668-74. 2014
  10. ncbi The spectrum of cognitive disorders in Parkinson's disease: a data-driven approach
    Kathy Dujardin
    Laboratoire de Neurosciences Fonctionnelles et Pathologies, University of Lille 2, EA4559, Lille, France
    Mov Disord 28:183-9. 2013

Detail Information

Publications44

  1. doi Apathy may herald cognitive decline and dementia in Parkinson's disease
    Kathy Dujardin
    Universite Lille Nord de France, France
    Mov Disord 24:2391-7. 2009
    ..These findings suggest that in nondemented, nondepressed PD patients, apathy may be a predictive factor for dementia and cognitive decline over time...
  2. ncbi Is the paced auditory serial addition test (PASAT) a valid means of assessing executive function in Parkinson's disease?
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, Lille, France
    Cortex 43:601-6. 2007
    ..Our results demonstrate the high sensitivity of the PASAT to cognitive impairment. However, correlation analyses showed that the main factor explaining the PD patients' PASAT impairment was cognitive slowing...
  3. ncbi [Apathy an neurodegenerative diseases: pathophysiology, diagnostic evaluation, and treatment]
    K Dujardin
    Faculte de Medecine, Université du Droit et de la Santé de Lille, Institut Fédératif de Recherche IFR 114, Neurosciences, Cedex
    Rev Neurol (Paris) 163:513-21. 2007
    ..The treatment of apathy per se remains anecdotal and, to date, little research into the efficacy of medication therapy has been performed...
  4. ncbi Characteristics of apathy in Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and Lille University Hospital, Lille, France
    Mov Disord 22:778-84. 2007
    ..Although the neurochemical substrate of apathy remains poorly characterized, the strong link between apathy and cognitive impairment observed in several studies suggests the participation of nondopaminergic circuits...
  5. doi Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and University Medical Center, Lille, France
    J Neurol 257:79-84. 2010
    ..However, the CCI does not enable more accurate screening for PD-associated dementia...
  6. doi The Lille Apathy Rating Scale: validation of a caregiver-based version
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and Lille University Hospital, Lille, France
    Mov Disord 23:845-9. 2008
    ..The LARS-i was seen to have excellent psychometric properties and appears to be valid for use in PD with respect to the patient-based LARS and the informant- and clinician-rated versions of the AES...
  7. ncbi Deficits in decoding emotional facial expressions in Parkinson's disease
    Kathy Dujardin
    Neurology A Department, Neurology and Movement Disorders Unit, Salengro Hospital, EA 2683, Lille University Hospital, F 59037 Lille Cedex, France
    Neuropsychologia 42:239-50. 2004
    ..The aim of the present study was to assess the consequences of Parkinson's disease (PD) on ability to decode emotional facial expressions (EFEs)-a method commonly used to investigate non-verbal emotion processing...
  8. doi Methylphenidate : a treatment for Parkinson's disease?
    David Devos
    Department of Medical Pharmacology, EA 1046, Lille Nord de France University, CHU Lille, Lille, France
    CNS Drugs 27:1-14. 2013
    ..Pharmacogenetic tools could be of use in better defining study patients as a function of their dopaminergic metabolism and drug responsiveness...
  9. ncbi Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial
    David Devos
    Department of Medical Pharmacology, Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 85:668-74. 2014
    ..We sought to establish whether rivastigmine's ability to inhibit acetyl- and butyrylcholinesterases could relieve the symptoms of apathy in dementia-free, non-depressed patients with advanced PD...
  10. ncbi The spectrum of cognitive disorders in Parkinson's disease: a data-driven approach
    Kathy Dujardin
    Laboratoire de Neurosciences Fonctionnelles et Pathologies, University of Lille 2, EA4559, Lille, France
    Mov Disord 28:183-9. 2013
    ..Our results confirm the heterogeneity of cognitive presentations in PD, ranging from cognitively intact patients with rather high levels of performance in each cognitive domain to very severely impaired patients...
  11. pmc Role of basal ganglia circuits in resisting interference by distracters: a swLORETA study
    Perrine Bocquillon
    University of Lille Nord de France, Lille, France
    PLoS ONE 7:e34239. 2012
    ..Three-stimulus oddball paradigms can be used to study distracter-elicited and target-elicited P300 subcomponents...
  12. ncbi The pattern of attentional deficits in Parkinson's disease
    Kathy Dujardin
    Laboratoire de Neurosciences Fonctionnelles et Pathologies, EA 4559, University of Lille 2, Lille, France
    Parkinsonism Relat Disord 19:300-5. 2013
    ..We also sought to identify the main demographic and clinical characteristics associated with attention deficits in Parkinson's disease...
  13. pmc Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
    Caroline Moreau
    Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 84:552-5. 2013
    ..Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD)...
  14. ncbi Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients
    Melissa Tir
    Department of Neurology, Salengro Hospital, Lille University Medical Centre, Lille, France
    Neurosurgery 61:297-304; discussion 304-5. 2007
    ..The primary objective was to describe the clinical outcome in terms of efficacy and tolerance in STN-DBS patients. A secondary objective was to discuss presurgery clinical characteristics a posteriori as a function of outcome...
  15. doi Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study
    David Devos
    Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France
    Mov Disord 23:850-7. 2008
    ..A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage...
  16. doi Use of swLORETA to localize the cortical sources of target- and distracter-elicited P300 components
    Perrine Bocquillon
    Universite Lille Nord de France, UDSL, Ibis Rue Georges Lefevre 59000 Lille, France
    Clin Neurophysiol 122:1991-2002. 2011
    ..Cognitive event-related potentials (especially P300) have long been used to explore attentional processes. The aim of this study was to identify the cortical areas involved in P300 generation during a selective attention task...
  17. pmc Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease
    K Dujardin
    Neurology and Movement Disorders Unit, EA2683, University of Lille 2 and Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 75:202-8. 2004
    ..Although adverse effects are infrequent, some behavioural disturbances have been reported...
  18. doi Parkinson's disease dementia can be easily detected in routine clinical practice
    Kathy Dujardin
    Universite Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France
    Mov Disord 25:2769-76. 2010
    ....
  19. ncbi Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, EA2683, Lille, France
    J Neurol 253:1154-9. 2006
    ....
  20. ncbi A case of severe dysexecutive syndrome consecutive to chronic bilateral pallidal stimulation
    K Dujardin
    Neurologie A, CHRU de Lille, Hopital Salengro, 59037 Lille, Cedex, France
    Neuropsychologia 38:1305-15. 2000
    ..When the stimulation was turned off, the impairment was partly reversible. This observation emphasizes the role of the GPi in executive function...
  21. ncbi Rapid eye movement sleep behavior disorder in treatment-naïve Parkinson disease patients
    Lucie Plomhause
    EA 4559, Lille Nord de France University, Lille, France Department of Clinical Neurophysiology, Lille University Medical Center, Lille, France
    Sleep Med 14:1035-7. 2013
    ..The objectives of our study were to prospectively evaluate the frequency of RBD in a sample of treatment-naïve, newly diagnosed PD patients and compare sleep characteristics and cognition in RBD and non-RBD groups...
  22. doi Attention modulates step initiation postural adjustments in Parkinson freezers
    Céline Tard
    Universite Lille Nord de France, UDSL, France Troubles cognitifs dégénératifs et vasculaires, EA1046, Lille 2, France Neurology and Movement Disorders Department, Lille University Medical Center, France
    Parkinsonism Relat Disord 20:284-9. 2014
    ..Our main objective was to establish whether or not a change in attentional load during step initiation modulates APAs differently in patients with vs. without freezing of gait...
  23. doi Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
    Caroline Moreau
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France
    Lancet Neurol 11:589-96. 2012
    ....
  24. ncbi Executive function differences in multiple system atrophy and Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Clinique Neurologique, Neurologie A, Hopital Salengro, CHRU de Lille, 59037 Lille Cedex, France
    Parkinsonism Relat Disord 9:205-11. 2003
    ..This study suggests that despite the evidence of some differences in executive function in MSA and PD, the contribution of standard neuropsychological examination to the differential diagnosis of both syndromes remains still limited...
  25. doi Assessing apathy in everyday clinical practice with the short-form Lille Apathy Rating Scale
    Kathy Dujardin
    Laboratoire de Neurosciences Fonctionnelles et Pathologies, EA 4559, Université Lille, Lille, France Neurologie et Pathologie du Mouvement, Neurologie A, Hopital Salengro, Centre Hospitalier Universitaire, Lille, France
    Mov Disord 28:2014-9. 2013
    ..The aim of the present study was to validate a short form of the LARS for use in everyday practice...
  26. doi Role of attentional resources on gait performance in Huntington's disease
    Arnaud Delval
    Department of Neurology and Movement Disorders, Salengro Hospital, Lille Regional University Hospital, Lille Cedex, France
    Mov Disord 23:684-9. 2008
    ..Patients with HD had greater difficulty walking while performing a concurrent cognitive task; the drain on attentional resources deteriorated walking performance...
  27. ncbi Gait abnormalities induced by acquired bilateral pallidal lesions: a motion analysis study
    P Krystkowiak
    Neurologie A, Hopital R Salengro, CHRU de Lille, 59037, Lille Cedex, France
    J Neurol 253:594-600. 2006
    ..However, the precise clinical features of these disorders (and the role of the pallidum therein) remain to be established...
  28. pmc The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease
    P Sockeel
    Psychology Department, Charles De Gaulle University, and Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, France
    J Neurol Neurosurg Psychiatry 77:579-84. 2006
    ..It is a frequent consequence of neurological and psychiatric disorders. Although various scoring methods have been proposed, there is a lack of validated, standardised instruments for detecting apathy and assessing its severity...
  29. ncbi Stimulation of the subthalamic nucleus in Parkinson's disease: cognitive and affective changes are not linked to the motor outcome
    M P Perriol
    Neurology and Movement Disorders Unit, EA2683, University of Lille 2 and Lille University Hospital, Lille, France
    Parkinsonism Relat Disord 12:205-10. 2006
    ..Subthalamic nucleus deep brain stimulation (STN0 DBS) is a widely performed surgical treatment in PD. However, the relationship between motor results and cognitive/behavioural modifications is unclear...
  30. doi [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study]
    H Zephir
    Clinique Neurologique, Hopital Roger Salengro, CHRU de Lille, université Lille 2 EA 2686, 59047 Lille Cedex, France
    Rev Neurol (Paris) 164:47-52. 2008
    ..We suggest that mitoxantrone combined with methylprednisolone has a potential positive effect on cognitive functions...
  31. doi Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon
    Clemence Simonin
    Department of Neurology and Movement Disorders, Salengro Hospital, EA 2683, Lille University Medical Center, Lille, France
    J Neurol 256:1736-41. 2009
    ..Our results suggest that DBS leads to both qualitative and quantitative modulations in the corticostriatal loops...
  32. doi [Classification of parkinsonian syndromes via factorial discriminant analysis of brain SPECT data]
    A Kreisler
    EA 2683, Service de Neurologie et Pathologie du Mouvement, Hopital Roger Salengro, CHU de Lille, 59037 Lille Cedex, France
    Rev Neurol (Paris) 165:440-8. 2009
    ....
  33. pmc Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease
    D Devos
    Department of Neurology, Institute of Predictive Medicine and Therapeutic Research, Lille University Medical Centre, Lille, France
    J Neurol Neurosurg Psychiatry 78:470-5. 2007
    ..Gait disorders could also be partly related to norepinephrine system impairment, and the pharmacological modulation of both dopamine and norepinephrine pathways could potentially improve the symptomatology...
  34. ncbi Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis
    Nicolas Carriere
    Service de Neurologie et Pathologie du Mouvement, Centre Hospitalier Regional Universitaire, Lille, France Université Lille Nord de France, EA 1046, Lille, France
    Mov Disord 29:897-903. 2014
    ..Dopa-resistant apathy in PD was associated with atrophy of the left nucleus accumbens and the dorsolateral head of the left caudate. © 2014 International Parkinson and Movement Disorder Society. ..
  35. doi Attention impairment in temporal lobe epilepsy: a neurophysiological approach via analysis of the P300 wave
    Perrine Bocquillon
    Department of Clinical Neurophysiology, Lille University Medical Center, Lille, France
    Hum Brain Mapp 30:2267-77. 2009
    ..Our hypothesis was that temporal lobe dysfunction would modify the P3 source regions in TLE patients...
  36. doi SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes
    Eugénie Mutez
    UMR 837 INSERM, Team 6, JParc, IRCL, Lille, France
    Hum Mutat 32:E2079-90. 2011
    ..Our detailed genomic analysis and clinical exploration enabled us to specify the genotype-phenotype relationship, identify a case of presymptomatic PD and gain insight into the role of LINEs in SNCA locus duplication...
  37. pmc Targeting chelatable iron as a therapeutic modality in Parkinson's disease
    David Devos
    1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France
    Antioxid Redox Signal 21:195-210. 2014
    ..Antioxid. Redox Signal. 21, 195-210. ..
  38. ncbi Dysfunction of the human memory systems: role of the dopaminergic transmission
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Neurology A Department, Salengro Hospital, Lille University Hospital, Lille, France
    Curr Opin Neurol 16:S11-6. 2003
    ..Other neurotransmission systems are probably involved in the pathophysiology of cognitive dysfunction in Parkinson's disease, and currently it is the cholinergic hypothesis that is the most considered...
  39. doi Slowly progressive spinocerebellar ataxia with extrapyramidal signs and mild cognitive impairment (SCA21)
    J Delplanque
    INSERM U837, Jean Pierre Aubert Research Center, Lille, France
    Cerebellum 7:179-83. 2008
    ..Therefore, the gene responsible for SCA21 remains to be identified...
  40. ncbi Clinical features and genetic analysis of a new form of spinocerebellar ataxia
    D Devos
    Clinique Neurologique, UF de Neurobiologie, Hopital R Salengro, CHRU, Lille, France
    Neurology 56:234-8. 2001
    ..The growing heterogeneity of the autosomal dominant forms of these diseases shows that the genetic etiologies of at least 20% of ADCA have yet to be elucidated...
  41. ncbi Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease
    Canan Ozsancak
    Service de Neurologie et Pathologie du Mouvement, EA 2683 Clinique Neurologique, CHU de Lille, 59037, Lille Cedex, France
    J Neurol 251:1317-23. 2004
    ....
  42. ncbi Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients
    Kathy Dujardin
    Neurologie et Pathologie du Mouvement Neurologie A, Hôpital Salengro Centre Hospitalier Universitaire, 59037, Lille Cedex, France
    J Neurol 251:1383-92. 2004
    ....
  43. ncbi Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease: a biomechanical study
    Arnaud Delval
    Department of Neurology and Movement, Disorders, EA 2683, Hospital R Salengro, Regional University Hospital, 59037, Lille Cedex, France
    J Neurol 253:73-80. 2006
    ..e. a decrease in the amplitude of movement) and bradykinesia (i. e. difficulty in executing a movement, slowness) in gait disturbance...
  44. doi Cognitive functions in neuromyelitis optica
    Frederic Blanc
    Department of Neurology, Strasbourg University, Alsace, France
    Arch Neurol 65:84-8. 2008
    ..To date, cognitive functions have never been investigated in NMO...